



Clinical trial results:

A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2009-017950-11 |
| Trial protocol | ES DE FR GB IT |
| Global end of trial date | 27 December 2016 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 30 December 2017 |
| First version publication date | 30 December 2017 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 113086 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | ViiV Healthcare |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, |
| Public contact | GSK Response Center, GlaxoSmithKline, 1 866-435-7343, |
| Scientific contact | GSK Response Center, GlaxoSmithKline, 1 866-435-7343, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 19 July 2017 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|------------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 27 December 2016 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To demonstrate the antiviral activity of GSK1349572 50 mg administered once daily compared to RAL 400 mg twice daily over 48 weeks in HIV-1 infected therapy naïve subjects

Protection of trial subjects:

An Independent Data Monitoring Committee (IDMC) was utilized in this study to ensure external objective medical and/or statistical review of safety and/or efficacy issues in order to protect the ethical and safety interests of participants and to protect the scientific validity of the study.

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 19 October 2010 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Australia: 37 |
| Country: Number of subjects enrolled | Canada: 61 |
| Country: Number of subjects enrolled | France: 93 |
| Country: Number of subjects enrolled | Germany: 95 |
| Country: Number of subjects enrolled | Italy: 48 |
| Country: Number of subjects enrolled | Russian Federation: 90 |
| Country: Number of subjects enrolled | Spain: 242 |
| Country: Number of subjects enrolled | United Kingdom: 17 |
| Country: Number of subjects enrolled | United States: 139 |
| Worldwide total number of subjects | 822 |
| EEA total number of subjects | 495 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|--|-----|
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 816 |
| From 65 to 84 years | 6 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

This was a randomized, parallel group, non-inferiority study to demonstrate the antiviral activity of Dolutegravir. Participants were enrolled from 9 countries. Participants in Dolutegravir arm who completed 96 Weeks double-blind phase continued to receive Dolutegravir in open-label phase, until dolutegravir was locally available commercially.

Pre-assignment

Screening details:

Total 1035 participants were screened; 827 participants were randomized, and 822 participants entered the treatment period. Of the 5 participants who were randomized but not treated with investigational product, 4 withdrew consent and 1 was randomized in error. 338 participants were enrolled in open label phase to receive Dolutegravir.

Period 1

| | |
|------------------------------|---------------------------------------|
| Period 1 title | Double-blind Phase: 96 Weeks Duration |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|----------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | DTG 50 mg once a day |

Arm description:

Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/(3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Dolutegravir |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received Dolutegravir 50 mg once a day for 96 weeks in double-blind treatment phase. Participants who completed 96 weeks of the treatment phase were given the opportunity to receive Dolutegravir 50 mg once a day during an Open-label Phase of the study.

| | |
|--|-------------------------|
| Investigational medicinal product name | Tenofovir/Emtricitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received Tenofovir/Emtricitabine fixed-dose combination as a background therapy.

| | |
|--|---------------------|
| Investigational medicinal product name | Abacavir/Lamivudine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received Abacavir/Lamivudine fixed-dose combination as a background therapy.

| | |
|---|-------------------------|
| Arm title | RTG 400 mg BID |
| Arm description: Participants received RTG 400 mg BID in combination with NRTI therapy, with either ABC/3TC or TDF/FTC. | |
| Arm type | Active comparator |
| Investigational medicinal product name | Raltegravir |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: Participants received Raltegravir 400 mg BID for 96 weeks in double-blind treatment phase. | |
| Investigational medicinal product name | Tenofovir/Emtricitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: Participants received Tenofovir/Emtricitabine fixed-dose combination as a background therapy. | |
| Investigational medicinal product name | Abacavir/Lamivudine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: Participants received Abacavir/Lamivudine fixed-dose combination as a background therapy. | |

| Number of subjects in period 1 | DTG 50 mg once a day | RTG 400 mg BID |
|--|----------------------|----------------|
| Started | 411 | 411 |
| Completed | 304 | 332 |
| Not completed | 107 | 79 |
| Adverse event, serious fatal | 1 | 1 |
| Consent withdrawn by subject | 18 | 14 |
| Physician decision | 3 | - |
| Met Protocol-defined Stopping Criteria | 6 | 3 |
| Adverse event, non-fatal | 11 | 6 |
| Lost to follow-up | 22 | 10 |
| Study Closed/Terminated | 6 | 4 |
| Lack of efficacy | 22 | 25 |
| Protocol deviation | 18 | 16 |

Period 2

| | |
|------------------------------|---------------------------------------|
| Period 2 title | Open-label Phase: median of 1267 days |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------|-----------------------------------|
| Arm title | DTG 50 mg once a day (Open-label) |
|------------------|-----------------------------------|

Arm description:

Participants who successfully completed 96 weeks of double blind phase continued to receive DTG 50 mg once a day during open label phase, until dolutegravir was locally available commercially. Participants received DTG 50 mg once a day in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Dolutegravir |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received Dolutegravir 50 mg once a day for 96 weeks in double-blind treatment phase. Participants who completed 96 weeks of the treatment phase were given the opportunity to receive Dolutegravir 50 mg once a day during an Open-label Phase of the study.

| | |
|--|---------------------|
| Investigational medicinal product name | Abacavir/Lamivudine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received Abacavir/Lamivudine fixed-dose combination as a background therapy.

| | |
|--|-------------------------|
| Investigational medicinal product name | Tenofovir/Emtricitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received Tenofovir/Emtricitabine fixed-dose combination as a background therapy.

| Number of subjects in period 2 | DTG 50 mg once a day (Open-label) |
|--|-----------------------------------|
| Started | 338 |
| Completed | 294 |
| Not completed | 44 |
| Consent withdrawn by subject | 8 |
| Physician decision | 3 |
| Met Protocol-defined Stopping Criteria | 4 |
| Adverse event, non-fatal | 4 |
| Lost to follow-up | 15 |

| | |
|--------------------|---|
| Lack of efficacy | 5 |
| Protocol deviation | 5 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|----------------------|
| Reporting group title | DTG 50 mg once a day |
|-----------------------|----------------------|

Reporting group description:

Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/(3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.

| | |
|-----------------------|----------------|
| Reporting group title | RTG 400 mg BID |
|-----------------------|----------------|

Reporting group description:

Participants received RTG 400 mg BID in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.

| Reporting group values | DTG 50 mg once a day | RTG 400 mg BID | Total |
|------------------------------------|----------------------|----------------|-------|
| Number of subjects | 411 | 411 | 822 |
| Age categorical Units: Subjects | | | |

| | | | |
|---|----------------|-----------------|-----|
| Age continuous Units: years arithmetic mean standard deviation | 37.3 ± 9.19 | 36.6 ± 10.02 | - |
| Gender categorical Units: | | | |
| Female | 63 | 56 | 119 |
| Male | 348 | 355 | 703 |
| Race, Customized Units: Subjects | | | |
| African American/African Heritage (Her) | 49 | 39 | 88 |
| American Indian or Alaska Native | 7 | 9 | 16 |
| Central/South Asian Her | 2 | 0 | 2 |
| Japanese/East Asian Her/South East Asian Her | 4 | 10 | 14 |
| Native Hawaiian or other Pacific Islander | 2 | 0 | 2 |
| White | 346 | 352 | 698 |
| African American/African Her and Asian and White | 1 | 0 | 1 |
| Asian and White | 0 | 1 | 1 |

End points

End points reporting groups

| | |
|---|-----------------------------------|
| Reporting group title | DTG 50 mg once a day |
| Reporting group description: Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/(3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study. | |
| Reporting group title | RTG 400 mg BID |
| Reporting group description: Participants received RTG 400 mg BID in combination with NRTI therapy, with either ABC/3TC or TDF/FTC. | |
| Reporting group title | DTG 50 mg once a day (Open-label) |
| Reporting group description: Participants who successfully completed 96 weeks of double blind phase continued to receive DTG 50 mg once a day during open label phase, until dolutegravir was locally available commercially. Participants received DTG 50 mg once a day in combination with NRTI therapy, with either ABC/3TC or TDF/FTC. | |

Primary: Percentage of participants with Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 copies (c)/milliliter (mL) through Week 48

| | |
|---|---|
| End point title | Percentage of participants with Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 copies (c)/milliliter (mL) through Week 48 |
| End point description: Percentage of participants with plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) with <50 c/mL was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) snapshot algorithm. The algorithm treats all participants without HIV-1 RNA data as non-responders, as well as participants who switch their concomitant Antiretroviral Therapy (ART) prior to Week 48 as follows: background ART substitutions not permitted per study; background ART substitutions permitted per study unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the subject was on-treatment. Intent-to-Treat Exposed (ITT-E) Population comprised all randomized participants who received at least one dose of study medication. | |
| End point type | Primary |
| End point timeframe: Baseline up to Week 48 | |

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|-----------------------------------|----------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[1] | 411 | | |
| Units: Percentage of participants | | | | |
| number (not applicable) | 88 | 85 | | |

Notes:

[1] - ITT-E Population.

Statistical analyses

| | |
|--|---------------------------------------|
| Statistical analysis title | Statistical analysis 1 |
| Statistical analysis description: | |
| Analysis was based on Cochran-Mantel Haenszel stratified analysis adjusted for the following Baseline stratification factors: Baseline HIV-1 RNA and background dual NRTI. | |
| Comparison groups | DTG 50 mg once a day v RTG 400 mg BID |
| Number of subjects included in analysis | 822 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[2] |
| Parameter estimate | Difference in percentage |
| Point estimate | 2.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.2 |
| upper limit | 7.1 |

Notes:

[2] - Non-inferiority could be concluded if the lower bound of a two-sided 95% confidence interval for the difference (DTG - RAL) in percentages between the two treatment arms was > -10%.

Secondary: Number of participants with detectable HIV-1 virus that has genotypic or phenotypic evidence of INI resistance

| | |
|---|--|
| End point title | Number of participants with detectable HIV-1 virus that has genotypic or phenotypic evidence of INI resistance |
| End point description: | |
| Number of participants with detectable virus that has genotypic or phenotypic evidence of Integrase Inhibitor (INI) resistance were assessed at Week 48 and Week 96. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the deoxyribonucleic acid (DNA) of the host cell. | |
| End point type | Secondary |
| End point timeframe: | |
| Week 48 and Week 96 | |

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|-----------------------------|----------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[3] | 411 | | |
| Units: Participants | | | | |
| Week 48, genotypic | 0 | 1 | | |
| Week 48, phenotypic | 1 | 2 | | |
| Week 96, genotypic | 0 | 1 | | |
| Week 96, phenotypic | 1 | 2 | | |

Notes:

[3] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA <50 c/mL

| | |
|-----------------|---|
| End point title | Number of participants with plasma HIV-1 RNA <50 c/mL |
|-----------------|---|

End point description:

The number of participants with plasma HIV-1 RNA level <50 c/mL was assessed at Week 96.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 96

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|-----------------------------|-------------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[4] | 411 | | |
| Units: Participants | 332 | 314 | | |

Notes:

[4] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA <400 c/mL

| | |
|-----------------|--|
| End point title | Number of participants with plasma HIV-1 RNA <400 c/mL |
|-----------------|--|

End point description:

The number of participants with plasma HIV-1 RNA level <400 c/mL was assessed at Week 48 and Week 96.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 48 and Week 96

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|-----------------------------|-------------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[5] | 411 | | |
| Units: Participants | | | | |
| Week 48 | 369 | 356 | | |
| Week 96 | 338 | 321 | | |

Notes:

[5] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in plasma HIV-1 RNA over time

| | |
|-----------------|--|
| End point title | Change from Baseline in plasma HIV-1 RNA over time |
|-----------------|--|

End point description:

Change from Baseline in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as the measurements performed on Day 1. Change

from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96 | |

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|--------------------------------------|-------------------------|----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[6] | 411 | | |
| Units: log10 c/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline n=411, 411 | 4.538 (± 0.7258) | 4.599 (± 0.7048) | | |
| Week 4, n=402, 406 | -2.817 (± 0.6198) | -2.801 (± 0.6041) | | |
| Week 8, n=397, 402 | -2.897 (± 0.6837) | -2.886 (± 0.6754) | | |
| Week 12, n=396, 395 | -2.908 (± 0.6863) | -2.918 (± 0.6834) | | |
| Week 16, n=395, 388 | -2.917 (± 0.6949) | -2.943 (± 0.6841) | | |
| Week 24, n=393, 390 | -2.896 (± 0.7889) | -2.933 (± 0.7398) | | |
| Week 32, n=386, 377 | -2.907 (± 0.7609) | -2.947 (± 0.7613) | | |
| Week 40, n=375, 358 | -2.920 (± 0.7219) | -2.946 (± 0.6700) | | |
| Week 48, n=374, 358 | -2.915 (± 0.7237) | -2.942 (± 0.6737) | | |
| Week 60, n=366, 355 | -2.912 (± 0.7344) | -2.937 (± 0.6685) | | |
| Week 72, n=361, 350 | -2.917 (± 0.7261) | -2.932 (± 0.6728) | | |
| Week 84, n=352, 338 | -2.932 (± 0.7073) | -2.916 (± 0.6646) | | |
| Week 96, n=342, 329 | -2.938 (± 0.7004) | -2.901 (± 0.7072) | | |

Notes:

[6] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute values in plasma HIV-1 RNA over time

| | |
|--|---|
| End point title | Absolute values in plasma HIV-1 RNA over time |
| End point description: | |
| Absolute values in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles). | |
| End point type | Secondary |

End point timeframe:

Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|--------------------------------------|-------------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[7] | 411 | | |
| Units: log ₁₀ c/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline n=411, 411 | 4.538 (± 0.7258) | 4.599 (± 0.7048) | | |
| Week 4, n=402, 406 | 1.718 (± 0.2593) | 1.800 (± 0.4095) | | |
| Week 8, n=397, 402 | 1.646 (± 0.2006) | 1.709 (± 0.3791) | | |
| Week 12, n=396, 395 | 1.626 (± 0.1323) | 1.672 (± 0.3125) | | |
| Week 16, n=395, 388 | 1.620 (± 0.1252) | 1.648 (± 0.2647) | | |
| Week 24, n=393, 390 | 1.643 (± 0.2950) | 1.655 (± 0.3476) | | |
| Week 32, n=386, 377 | 1.620 (± 0.1917) | 1.636 (± 0.2721) | | |
| Week 40, n=375, 358 | 1.603 (± 0.0821) | 1.601 (± 0.0784) | | |
| Week 48, n=374, 358 | 1.606 (± 0.0866) | 1.599 (± 0.0582) | | |
| Week 60, n=366, 355 | 1.605 (± 0.1134) | 1.599 (± 0.0560) | | |
| Week 72, n=361, 350 | 1.601 (± 0.0803) | 1.605 (± 0.0836) | | |
| Week 84, n=352, 338 | 1.607 (± 0.1337) | 1.614 (± 0.1279) | | |
| Week 96, n=342, 329 | 1.599 (± 0.830) | 1.630 (± 0.2515) | | |

Notes:

[7] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in cluster of differentiation (CD)4+ cell counts over time

| | |
|-----------------|---|
| End point title | Change from Baseline in cluster of differentiation (CD)4+ cell counts over time |
|-----------------|---|

End point description:

CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the participants disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start ART. Changes from Baseline in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96 | |

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|--|----------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[8] | 411 | | |
| Units: Cells per cubic millimeter (cells/mm ³) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline n=411, 411 | 379.2 (± 178.32) | 374.3 (± 163.37) | | |
| Week 4, n=398, 403 | 93.3 (± 116.27) | 97.2 (± 129.35) | | |
| Week 8, n=398, 402 | 121.6 (± 127.97) | 126.6 (± 134.59) | | |
| Week 12, n=392, 397 | 130.7 (± 131.49) | 145.1 (± 144.08) | | |
| Week 16, n=394, 392 | 155.1 (± 137.23) | 173.0 (± 159.10) | | |
| Week 24, n=392, 389 | 199.3 (± 161.23) | 204.2 (± 162.28) | | |
| Week 32, n=384, 375 | 223.4 (± 165.30) | 241.3 (± 167.64) | | |
| Week 40, n=371, 357 | 224.1 (± 173.59) | 239.8 (± 173.33) | | |
| Week 48, n=374, 357 | 238.9 (± 171.81) | 257.5 (± 178.69) | | |
| Week 60, n=367, 355 | 247.8 (± 184.11) | 264.2 (± 188.63) | | |
| Week 72, n=360, 350 | 247.8 (± 168.37) | 278.6 (± 182.76) | | |
| Week 84, n=351, 338 | 281.3 (± 175.07) | 292.9 (± 199.42) | | |
| Week 96, n=343, 328 | 292.2 (± 195.70) | 286.2 (± 192.45) | | |

Notes:

[8] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute values in CD4+ cell counts over time

| | |
|--|---|
| End point title | Absolute values in CD4+ cell counts over time |
| End point description: | |
| CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy absolute values in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles). | |
| End point type | Secondary |

End point timeframe:

Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|--------------------------------------|-------------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[9] | 411 | | |
| Units: cells/mm ³ | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline n=411, 411 | 379.2 (± 172.32) | 374.3 (± 163.37) | | |
| Week 4, n=398, 403 | 474.2 (± 199.06) | 471.8 (± 191.02) | | |
| Week 8, n=398, 402 | 502.3 (± 205.15) | 502.4 (± 187.99) | | |
| Week 12, n=392, 397 | 513.3 (± 218.75) | 518.3 (± 195.59) | | |
| Week 16, n=394, 392 | 536.4 (± 219.47) | 550.1 (± 221.77) | | |
| Week 24, n=392, 389 | 582.0 (± 232.93) | 580.8 (± 218.76) | | |
| Week 32, n=384, 375 | 606.5 (± 242.95) | 618.7 (± 237.56) | | |
| Week 40, n=371, 357 | 609.1 (± 239.11) | 623.1 (± 234.82) | | |
| Week 48, n=374, 357 | 623.8 (± 247.82) | 641.2 (± 241.75) | | |
| Week 60, n=367, 355 | 635.6 (± 241.27) | 648.5 (± 238.99) | | |
| Week 72, n=360, 350 | 635.2 (± 237.78) | 664.0 (± 239.86) | | |
| Week 84, n=351, 338 | 668.0 (± 246.50) | 677.5 (± 249.64) | | |
| Week 96, n=343, 328 | 679.8 (± 257.89) | 672.4 (± 237.54) | | |

Notes:

[9] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated post-Baseline HIV-associated conditions and progression, excluding recurrences

| | |
|-----------------|--|
| End point title | Number of participants with the indicated post-Baseline HIV-associated conditions and progression, excluding recurrences |
|-----------------|--|

End point description:

Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline to a CDC CAT C event (EV); CDC CAT B at Baseline to a CDC CAT C

EV; CDC CAT C at Baseline to a new CDC CAT C EV; or CDC CAT A, B, or C at Baseline to death.

| | |
|-----------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| From Baseline until Week 96 | |

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|--|-------------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[10] | 411 | | |
| Units: Participants | | | | |
| Any category condition | 10 | 8 | | |
| Any Category B condition | 3 | 3 | | |
| Any Category C condition | 6 | 4 | | |
| Any death | 1 | 1 | | |
| Progression from CAT A to CAT C | 4 | 2 | | |
| Progression from CAT B to CAT C | 3 | 1 | | |
| Progression from CAT C to new CAT C | 0 | 1 | | |
| Progression from CAT A, B, or C to death | 1 | 1 | | |

Notes:

[10] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated Grade 1 to 4 clinical chemistry and hematology toxicities/laboratory adverse events (AEs)

| | |
|-----------------|---|
| End point title | Number of participants with the indicated Grade 1 to 4 clinical chemistry and hematology toxicities/laboratory adverse events (AEs) |
|-----------------|---|

End point description:

All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), carbon dioxide (CO₂) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hyponatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxicities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Safety Population: all participants who received at least one dose of investigational product

| | |
|-----------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| From Baseline until Week 96 | |

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|-----------------------------|-------------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 411 ^[11] | 411 | | |
| Units: Participants | | | | |
| ALT | 57 | 70 | | |
| ALP | 7 | 15 | | |
| AST | 67 | 75 | | |
| CO2 content/bicarbonate | 58 | 67 | | |
| Cholesterol | 90 | 73 | | |
| CK | 61 | 47 | | |
| Creatinine | 11 | 7 | | |
| Hyperglycaemia | 70 | 87 | | |
| Hyperkalemia | 7 | 4 | | |
| Hypernatremia | 4 | 6 | | |
| Hypoglycaemia | 17 | 27 | | |
| Hypokalemia | 10 | 15 | | |
| Hyponatremia | 34 | 48 | | |
| LDL cholesterol calculation | 74 | 49 | | |
| Lipase | 55 | 62 | | |
| Phosphorus, inorganic | 65 | 71 | | |
| Total bilirubin | 27 | 24 | | |
| Triglycerides | 7 | 8 | | |
| Hemoglobin | 10 | 5 | | |
| Platelet count | 19 | 19 | | |
| Total neutrophils | 54 | 48 | | |
| White Blood Cell count | 19 | 7 | | |

Notes:

[11] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the plasma concentration-time curve from time zero to time tau [AUC(0-tau)] of DTG

| | |
|-----------------|---|
| End point title | Area under the plasma concentration-time curve from time zero to time tau [AUC(0-tau)] of DTG |
|-----------------|---|

End point description:

AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. The predicted individual AUC(0-tau) were obtained from the final population PK model by an empirical Bayes estimation. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hours post-dose was completed at Week 4, then the 4 to 12 hour post-dose must be obtained at Week 48, and vice versa. The Pharmacokinetic (PK) Concentration Population comprised of all participants who received DTG, had undergone PK sampling during the study, and provided evaluable DTG plasma concentration data.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 4, Week 24, and Week 48

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|--|-------------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 403 ^[12] | 0 ^[13] | | |
| Units: Micrograms*hour per milliliter (µg*hr/mL) | | | | |
| geometric mean (geometric coefficient of variation) | 53.6 (± 26.8) | () | | |

Notes:

[12] - PK Concentration Population

[13] - No participants were analyzed in this arm.

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum plasma concentration (Cmax) and concentration at the end of a dosing interval (Ctau) of DTG

| | |
|-----------------|---|
| End point title | Maximum plasma concentration (Cmax) and concentration at the end of a dosing interval (Ctau) of DTG |
|-----------------|---|

End point description:

The Cmax and Ctau of DTG were assessed at Week 48. The predicted individual Cmax and Ctau were obtained from the final population PK model by simulation of the concentration-time profiles. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hour post-dose was completed at Week 4, then the 4 to 12 hour post-dose must be obtained at Week 48, and vice versa.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 4, Week 24, and Week 48

| End point values | DTG 50 mg once a day | RTG 400 mg BID | | |
|--|-------------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 403 ^[14] | 0 ^[15] | | |
| Units: Micrograms per milliliter (µg/mL) | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cmax | 3.69 (± 19.6) | () | | |
| Ctau | 1.10 (± 46.5) | () | | |

Notes:

[14] - PK Concentration Population

[15] - No participants were analyzed for this arm.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the study (up to a median of 1267 days).

Adverse event reporting additional description:

AEs and non-serious AEs were collected in members of the Safety Population, which comprised of all participants who received at least one dose of investigational product.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 20.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------------------|
| Reporting group title | DTG 50mg once a day |
|-----------------------|---------------------|

Reporting group description:

Participants received DTG 50 mg one a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.

| | |
|-----------------------|----------------------------------|
| Reporting group title | DTG 50mg once a day (Open Label) |
|-----------------------|----------------------------------|

Reporting group description:

Participants who successfully completed 96 weeks of double blind phase continued to receive DTG 50 mg once a day during open label phase, until dolutegravir was locally available commercially. Participants received DTG 50 mg once a day in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.

| | |
|-----------------------|---------------|
| Reporting group title | RTG 400mg BID |
|-----------------------|---------------|

Reporting group description:

Participants received RTG 400 mg BID in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.

| Serious adverse events | DTG 50mg once a day | DTG 50mg once a day (Open Label) | RTG 400mg BID |
|---|---------------------|----------------------------------|-------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 41 / 411 (9.98%) | 21 / 338 (6.21%) | 45 / 411 (10.95%) |
| number of deaths (all causes) | 1 | 0 | 1 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anogenital warts | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cancer | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic malignant melanoma | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Papilloma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Keratoplasty | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| site conditions | | | |
| Chest pain | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Polyserositis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune reconstitution inflammatory syndrome | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Social circumstances | | | |
| Homicide | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Cervical dysplasia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Erectile dysfunction | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Menorrhagia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Suicide attempt | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Completed suicide | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Depression | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Laceration | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rib fracture | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intentional overdose | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower limb fracture | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple fractures | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Penis injury | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxicity to various agents | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper limb fracture | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Arrhythmia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| Seizure | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cognitive disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Status epilepticus | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| Vertigo | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Anal fissure | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal fistula | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal inflammation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Irritable bowel syndrome | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic pseudocyst | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peptic ulcer | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Proctitis ulcerative | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Hepatitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatotoxicity | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal colic | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal impairment | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 5 / 411 (1.22%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Anal abscess | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arthritis bacterial | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonsillar abscess | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia bacterial | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syphilis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abscess | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute hepatitis C | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atypical mycobacterial infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Corneal abscess | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Encephalitis viral | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis bacterial | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphadenitis viral | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis tuberculous | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neurosyphilis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteomyelitis chronic | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumocystis jirovecii pneumonia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia cytomegaloviral | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rhinitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Secondary syphilis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | DTG 50mg once a day | DTG 50mg once a day (Open Label) | RTG 400mg BID |
|---|---------------------|----------------------------------|--------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 353 / 411 (85.89%) | 256 / 338 (75.74%) | 344 / 411 (83.70%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Anogenital warts | | | |
| subjects affected / exposed | 16 / 411 (3.89%) | 8 / 338 (2.37%) | 22 / 411 (5.35%) |
| occurrences (all) | 17 | 9 | 24 |
| Skin papilloma | | | |
| subjects affected / exposed | 9 / 411 (2.19%) | 2 / 338 (0.59%) | 8 / 411 (1.95%) |
| occurrences (all) | 10 | 2 | 10 |
| Fibroma | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 1 | 2 |
| Lipoma | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 1 | 2 |
| Acrochordon | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 2 | 1 |
| Kaposi's sarcoma | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Oral papilloma | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Anal neoplasm | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cervix carcinoma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysplastic naevus | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye haemangioma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Fibroadenoma of breast | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fibrous histiocytoma | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemangioma of liver | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Haemangioma of spleen | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Keratoacanthoma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Papilloma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Penile wart | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Schwannoma | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Uterine leiomyoma | | | |

| | | | |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 7 / 411 (1.70%) | 5 / 338 (1.48%) | 12 / 411 (2.92%) |
| occurrences (all) | 7 | 6 | 12 |
| Varicose vein | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 2 | 1 |
| Flushing | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Hot flush | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Thrombophlebitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Circulatory collapse | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Phlebitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Surgical and medical procedures | | | |
| Tooth extraction | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Inguinal hernia repair | | | |

| | | | |
|--|------------------|-----------------|------------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal septal operation | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Papilloma excision | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tonsillectomy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 22 / 411 (5.35%) | 7 / 338 (2.07%) | 24 / 411 (5.84%) |
| occurrences (all) | 26 | 7 | 27 |
| Pyrexia | | | |
| subjects affected / exposed | 23 / 411 (5.60%) | 6 / 338 (1.78%) | 24 / 411 (5.84%) |
| occurrences (all) | 30 | 7 | 26 |
| Asthenia | | | |
| subjects affected / exposed | 14 / 411 (3.41%) | 7 / 338 (2.07%) | 18 / 411 (4.38%) |
| occurrences (all) | 16 | 7 | 19 |
| Influenza like illness | | | |
| subjects affected / exposed | 13 / 411 (3.16%) | 7 / 338 (2.07%) | 9 / 411 (2.19%) |
| occurrences (all) | 15 | 8 | 11 |
| Chest pain | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 3 / 338 (0.89%) | 2 / 411 (0.49%) |
| occurrences (all) | 5 | 3 | 2 |
| Feeling abnormal | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 3 | 0 | 2 |
| Malaise | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 3 | 0 | 1 |
| Local swelling | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |
| Pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 0 | 0 | 3 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 1 | 2 |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 3 |
| Cyst | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Granuloma | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Ill-defined disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Inflammation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Mucosal dryness | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Nodule | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Suprapubic pain | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Axillary pain | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Chills | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Oedema mucosal | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Polyp | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Swelling | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Immune system disorders | | | |
| Seasonal allergy | | | |
| subjects affected / exposed | 8 / 411 (1.95%) | 5 / 338 (1.48%) | 7 / 411 (1.70%) |
| occurrences (all) | 8 | 7 | 7 |
| Food allergy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 0 | 1 | 3 |

| | | | |
|--|----------------------|----------------------|----------------------|
| Drug hypersensitivity subjects affected / exposed occurrences (all) | 2 / 411 (0.49%) 2 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Immune reconstitution inflammatory syndrome subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 2 / 411 (0.49%) 2 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Jarisch-Herxheimer reaction subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Social circumstances Stress at work subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Reproductive system and breast disorders Erectile dysfunction subjects affected / exposed occurrences (all) | 5 / 411 (1.22%) 5 | 3 / 338 (0.89%) 3 | 6 / 411 (1.46%) 6 |
| Benign prostatic hyperplasia subjects affected / exposed occurrences (all) | 2 / 411 (0.49%) 2 | 2 / 338 (0.59%) 2 | 1 / 411 (0.24%) 1 |
| Cervical dysplasia subjects affected / exposed occurrences (all) | 2 / 411 (0.49%) 2 | 2 / 338 (0.59%) 2 | 0 / 411 (0.00%) 0 |
| Prostatitis subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 2 / 411 (0.49%) 2 |
| Gynaecomastia subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Menorrhagia subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Sexual dysfunction | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Testicular pain | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Vaginal discharge | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Balanoposthitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Breast mass | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Breast pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Breast tenderness | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Endometriosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Epididymal tenderness | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Genital lesion | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Genital rash | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypospermia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Menstruation irregular | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Ovarian cyst | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Penile discharge | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pelvic discomfort | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Prostatomegaly | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scrotal swelling | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Testicular oedema | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Testicular swelling | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Testis discomfort | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Varicocele | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vulval ulceration | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |

| | | | |
|---------------------------------------|------------------|-----------------|------------------|
| subjects affected / exposed | 23 / 411 (5.60%) | 9 / 338 (2.66%) | 22 / 411 (5.35%) |
| occurrences (all) | 27 | 9 | 24 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 19 / 411 (4.62%) | 6 / 338 (1.78%) | 16 / 411 (3.89%) |
| occurrences (all) | 22 | 7 | 19 |
| Asthma | | | |
| subjects affected / exposed | 8 / 411 (1.95%) | 1 / 338 (0.30%) | 4 / 411 (0.97%) |
| occurrences (all) | 10 | 1 | 4 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 11 / 411 (2.68%) |
| occurrences (all) | 2 | 0 | 13 |
| Nasal congestion | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 5 / 411 (1.22%) |
| occurrences (all) | 3 | 2 | 5 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 2 / 338 (0.59%) | 4 / 411 (0.97%) |
| occurrences (all) | 2 | 2 | 4 |
| Sinus congestion | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 3 | 1 | 3 |
| Epistaxis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 2 | 2 |
| Catarrh | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 1 | 2 |
| Allergic sinusitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 2 |
| Dysphonia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |

| | | | |
|------------------------------|-----------------|-----------------|-----------------|
| Lung disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Respiratory disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Tonsillar hypertrophy | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Atelectasis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Dry throat | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Emphysema | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Laryngospasm | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal dryness | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal obstruction | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Nocturnal dyspnoea | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|------------------------------------|------------------|-----------------|------------------|
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sleep apnoea syndrome | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper respiratory tract congestion | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 28 / 411 (6.81%) | 6 / 338 (1.78%) | 19 / 411 (4.62%) |
| occurrences (all) | 28 | 6 | 20 |
| Depression | | | |
| subjects affected / exposed | 26 / 411 (6.33%) | 8 / 338 (2.37%) | 18 / 411 (4.38%) |
| occurrences (all) | 26 | 8 | 18 |
| Anxiety | | | |
| subjects affected / exposed | 19 / 411 (4.62%) | 6 / 338 (1.78%) | 22 / 411 (5.35%) |
| occurrences (all) | 19 | 7 | 24 |
| Abnormal dreams | | | |
| subjects affected / exposed | 13 / 411 (3.16%) | 1 / 338 (0.30%) | 8 / 411 (1.95%) |
| occurrences (all) | 14 | 1 | 9 |
| Sleep disorder | | | |
| subjects affected / exposed | 7 / 411 (1.70%) | 1 / 338 (0.30%) | 8 / 411 (1.95%) |
| occurrences (all) | 7 | 1 | 8 |
| Libido decreased | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 1 / 338 (0.30%) | 10 / 411 (2.43%) |
| occurrences (all) | 3 | 1 | 10 |
| Stress | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 4 / 411 (0.97%) | 2 / 338 (0.59%) | 4 / 411 (0.97%) |
| occurrences (all) | 4 | 2 | 4 |
| Nightmare | | | |
| subjects affected / exposed | 6 / 411 (1.46%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 6 | 0 | 2 |
| Depressed mood | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 4 | 1 | 1 |
| Panic attack | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 1 | 2 |
| Acute stress disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 2 | 2 |
| Drug use disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 2 | 1 |
| Burnout syndrome | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Disorientation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 0 | 0 | 4 |
| Euphoric mood | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Irritability | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Suicidal ideation | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |
| Agitation | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Emotional disorder | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Adjustment disorder with depressed mood | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Aggression | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Agoraphobia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Alcohol withdrawal syndrome | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Alcoholic psychosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anxiety disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Apathy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Attention deficit/hyperactivity disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Confusional state | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hallucination | | | |

| | | | |
|--------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Major depression | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Mental disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Mental fatigue | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Middle insomnia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mood swings | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Nervousness | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Panic reaction | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Persistent depressive disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Phobia of flying | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sleep-related eating disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Somnambulism | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Substance-induced psychotic | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 2 |
| Terminal insomnia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Thinking abnormal | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Withdrawal syndrome | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hepatobiliary disorders | | | |
| Hepatic steatosis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 2 | 1 | 3 |
| Cholelithiasis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hepatitis toxic | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 3 |
| Biliary colic | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Drug-induced liver injury | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gallbladder polyp | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hepatic cyst | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hepatic lesion | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hepatocellular injury | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hepatomegaly | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 6 / 411 (1.46%) | 1 / 338 (0.30%) | 4 / 411 (0.97%) |
| occurrences (all) | 8 | 1 | 10 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 4 / 411 (0.97%) |
| occurrences (all) | 3 | 2 | 9 |
| Weight increased | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 0 / 338 (0.00%) | 5 / 411 (1.22%) |
| occurrences (all) | 4 | 0 | 5 |
| Weight decreased | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 4 | 1 | 3 |
| Blood pressure increased | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 3 | 0 | 3 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 3 / 338 (0.89%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 3 | 2 |
| Lipase increased | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 1 | 1 | 3 |
| Transaminases increased | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 1 | 2 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Urinary sediment present | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood phosphorus decreased | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood testosterone decreased | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|----------------------|----------------------|----------------------|
| Heart sounds abnormal subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Human papilloma virus test positive subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Liver function test increased subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Oestradiol increased subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 1 / 338 (0.30%) 1 | 0 / 411 (0.00%) 0 |
| Parasite stool test positive subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 1 / 338 (0.30%) 1 | 0 / 411 (0.00%) 0 |
| Protein urine present subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| QRS axis abnormal subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Shigella test positive subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Streptococcus test positive subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 1 / 338 (0.30%) 1 | 0 / 411 (0.00%) 0 |
| Urine analysis abnormal subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Vitamin D decreased subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Ligament sprain | | | |
| subjects affected / exposed | 6 / 411 (1.46%) | 6 / 338 (1.78%) | 5 / 411 (1.22%) |
| occurrences (all) | 6 | 8 | 5 |
| Muscle strain | | | |
| subjects affected / exposed | 7 / 411 (1.70%) | 3 / 338 (0.89%) | 3 / 411 (0.73%) |
| occurrences (all) | 7 | 3 | 3 |
| Limb injury | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 3 / 338 (0.89%) | 5 / 411 (1.22%) |
| occurrences (all) | 2 | 3 | 5 |
| Contusion | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 4 | 2 | 2 |
| Epicondylitis | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 3 / 338 (0.89%) | 0 / 411 (0.00%) |
| occurrences (all) | 4 | 3 | 0 |
| Laceration | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 4 | 0 | 2 |
| Arthropod bite | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 1 | 2 |
| Fall | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 2 | 2 |
| Rib fracture | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 1 | 3 |
| Skin abrasion | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 1 | 1 | 4 |
| Bone contusion | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 3 | 0 | 1 |
| Foot fracture | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 3 | 0 | 1 |

| | | | |
|----------------------------------|-----------------|-----------------|-----------------|
| Meniscus injury | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Back injury | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Concussion | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Exposure to communicable disease | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 2 |
| Hand fracture | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Injury | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Ligament rupture | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Post-traumatic neck syndrome | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Road traffic accident | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Scar | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Tendon rupture | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Thermal burn | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Upper limb fracture | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Accident | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Animal bite | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Arthropod sting | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Bone fissure | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Burns second degree | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cartilage injury | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ear injury | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Excoriation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Eye contusion | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-------------------------------|-----------------|-----------------|-----------------|
| Eye injury | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fracture | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Head injury | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Human bite | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Joint injury | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Lower limb fracture | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neck injury | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Patella fracture | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Penis injury | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Poisoning | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Post lumbar puncture syndrome | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|----------------------|----------------------|----------------------|
| Post procedural discomfort subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Post-traumatic pain subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Scratch subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 1 / 338 (0.30%) 1 | 0 / 411 (0.00%) 0 |
| Subdural haematoma subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Tendon injury subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Traumatic haematoma subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Ulnar nerve injury subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Wound subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Congenital, familial and genetic disorders | | | |
| Hereditary non-polyposis colorectal cancer syndrome subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Ichthyosis subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Kidney duplex subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Odontogenic cyst | | | |

| | | | |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 1 / 338 (0.30%) 1 | 0 / 411 (0.00%) 0 |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 4 / 411 (0.97%) |
| occurrences (all) | 1 | 1 | 4 |
| Palpitations | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 1 | 2 |
| Tachycardia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Cardiomyopathy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Myocarditis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ventricular hypokinesia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 56 / 411 (13.63%) | 9 / 338 (2.66%) | 55 / 411 (13.38%) |
| occurrences (all) | 63 | 9 | 70 |
| Dizziness | | | |
| subjects affected / exposed | 24 / 411 (5.84%) | 0 / 338 (0.00%) | 24 / 411 (5.84%) |
| occurrences (all) | 25 | 0 | 24 |
| Sciatica | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 4 / 338 (1.18%) | 7 / 411 (1.70%) |
| occurrences (all) | 4 | 4 | 9 |
| Migraine | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 1 / 338 (0.30%) | 5 / 411 (1.22%) |
| occurrences (all) | 5 | 1 | 10 |
| Lethargy | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 6 / 411 (1.46%) |
| occurrences (all) | 3 | 0 | 7 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 5 | 2 | 2 |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 5 / 411 (1.22%) |
| occurrences (all) | 1 | 0 | 6 |
| Somnolence | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 4 | 0 | 2 |
| Disturbance in attention | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 4 / 411 (0.97%) |
| occurrences (all) | 1 | 0 | 5 |
| Dysgeusia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 4 / 411 (0.97%) |
| occurrences (all) | 1 | 0 | 4 |
| Facial paralysis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 1 | 2 |
| Amnesia | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 3 | 0 | 1 |
| Cervicobrachial syndrome | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 2 | 1 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 2 | 1 |
| Syncope | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Balance disorder | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Burning sensation | | | |

| | | | |
|---------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Cognitive disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dysaesthesia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 2 |
| Neuralgia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Poor quality sleep | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Agnosia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anosmia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Apraxia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Brain injury | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Cervical radiculopathy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Circadian rhythm sleep disorder | | | |

| | | | |
|-------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cluster headache | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dystonia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperaesthesia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Morton's neuralgia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nerve compression | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Peroneal nerve palsy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Post herpetic neuralgia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Presyncope | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sensory disturbance | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Trigeminal neuralgia | | | |

| | | | |
|--------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Vascular headache | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 9 / 411 (2.19%) | 3 / 338 (0.89%) | 4 / 411 (0.97%) |
| occurrences (all) | 13 | 4 | 4 |
| Anaemia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 4 / 411 (0.97%) |
| occurrences (all) | 0 | 0 | 4 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 1 | 2 |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 0 | 2 |
| Lymphadenitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Granulocytopenia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Polycythaemia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Red blood cell abnormality | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|--|----------------------|----------------------|----------------------|
| Thrombocytopenia subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Thymus disorder subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Ear and labyrinth disorders | | | |
| Vertigo subjects affected / exposed occurrences (all) | 6 / 411 (1.46%) 6 | 1 / 338 (0.30%) 1 | 5 / 411 (1.22%) 5 |
| Tinnitus subjects affected / exposed occurrences (all) | 5 / 411 (1.22%) 5 | 0 / 338 (0.00%) 0 | 4 / 411 (0.97%) 5 |
| Ear pain subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 2 / 338 (0.59%) 2 | 0 / 411 (0.00%) 0 |
| Hypoacusis subjects affected / exposed occurrences (all) | 2 / 411 (0.49%) 2 | 1 / 338 (0.30%) 1 | 0 / 411 (0.00%) 0 |
| Deafness subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 2 / 411 (0.49%) 2 |
| Ear disorder subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Excessive cerumen production subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Eustachian tube obstruction subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| External ear inflammation subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| External ear pain | | | |

| | | | |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 1 / 338 (0.30%) 1 | 0 / 411 (0.00%) 0 |
| Middle ear effusion subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Tympanic membrane disorder subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Eye disorders | | | |
| Vision blurred subjects affected / exposed occurrences (all) | 2 / 411 (0.49%) 2 | 0 / 338 (0.00%) 0 | 5 / 411 (1.22%) 5 |
| Conjunctivitis allergic subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 1 / 338 (0.30%) 1 | 2 / 411 (0.49%) 2 |
| Ocular hyperaemia subjects affected / exposed occurrences (all) | 3 / 411 (0.73%) 3 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Visual acuity reduced subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 1 / 338 (0.30%) 1 | 1 / 411 (0.24%) 1 |
| Chalazion subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 2 / 338 (0.59%) 2 | 0 / 411 (0.00%) 0 |
| Conjunctival haemorrhage subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Conjunctival hyperaemia subjects affected / exposed occurrences (all) | 2 / 411 (0.49%) 2 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Dry eye subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Eye pruritus subjects affected / exposed occurrences (all) | 2 / 411 (0.49%) 2 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Blepharitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Cataract | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Corneal erosion | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye inflammation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Eye pain | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eyelids pruritus | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypermetropia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ocular discomfort | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Photophobia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Retinal tear | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|--|-------------------------|------------------------|-------------------------|
| Retinal haemorrhage subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Scleritis subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Diarrhoea subjects affected / exposed occurrences (all) | 58 / 411 (14.11%) 72 | 21 / 338 (6.21%) 25 | 54 / 411 (13.14%) 65 |
| Nausea subjects affected / exposed occurrences (all) | 60 / 411 (14.60%) 70 | 3 / 338 (0.89%) 3 | 55 / 411 (13.38%) 66 |
| Abdominal pain subjects affected / exposed occurrences (all) | 18 / 411 (4.38%) 21 | 7 / 338 (2.07%) 7 | 16 / 411 (3.89%) 20 |
| Vomiting subjects affected / exposed occurrences (all) | 16 / 411 (3.89%) 21 | 5 / 338 (1.48%) 7 | 18 / 411 (4.38%) 19 |
| Constipation subjects affected / exposed occurrences (all) | 15 / 411 (3.65%) 16 | 1 / 338 (0.30%) 1 | 14 / 411 (3.41%) 17 |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 12 / 411 (2.92%) 13 | 5 / 338 (1.48%) 5 | 12 / 411 (2.92%) 14 |
| Haemorrhoids subjects affected / exposed occurrences (all) | 15 / 411 (3.65%) 15 | 5 / 338 (1.48%) 6 | 9 / 411 (2.19%) 9 |
| Flatulence subjects affected / exposed occurrences (all) | 12 / 411 (2.92%) 12 | 1 / 338 (0.30%) 1 | 11 / 411 (2.68%) 11 |
| Dyspepsia subjects affected / exposed occurrences (all) | 6 / 411 (1.46%) 6 | 2 / 338 (0.59%) 3 | 11 / 411 (2.68%) 11 |
| Toothache | | | |

| | | | |
|----------------------------------|------------------|-----------------|------------------|
| subjects affected / exposed | 9 / 411 (2.19%) | 6 / 338 (1.78%) | 3 / 411 (0.73%) |
| occurrences (all) | 10 | 6 | 3 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 1 / 338 (0.30%) | 12 / 411 (2.92%) |
| occurrences (all) | 4 | 1 | 12 |
| Abdominal distension | | | |
| subjects affected / exposed | 6 / 411 (1.46%) | 4 / 338 (1.18%) | 6 / 411 (1.46%) |
| occurrences (all) | 6 | 5 | 7 |
| Proctitis | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 4 / 338 (1.18%) | 5 / 411 (1.22%) |
| occurrences (all) | 5 | 4 | 6 |
| Anogenital dysplasia | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 5 / 338 (1.48%) | 4 / 411 (0.97%) |
| occurrences (all) | 3 | 5 | 4 |
| Abdominal discomfort | | | |
| subjects affected / exposed | 10 / 411 (2.43%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 11 | 0 | 1 |
| Anal fissure | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 6 / 411 (1.46%) |
| occurrences (all) | 3 | 2 | 6 |
| Gastritis | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 5 / 338 (1.48%) | 1 / 411 (0.24%) |
| occurrences (all) | 4 | 5 | 1 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 4 / 411 (0.97%) |
| occurrences (all) | 3 | 2 | 6 |
| Odynophagia | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 1 / 338 (0.30%) | 4 / 411 (0.97%) |
| occurrences (all) | 3 | 1 | 4 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 2 / 338 (0.59%) | 3 / 411 (0.73%) |
| occurrences (all) | 2 | 2 | 3 |
| Dental caries | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 3 | 0 | 3 |
| Abdominal pain lower | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 1 | 1 | 3 |
| Enteritis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 2 | 2 |
| Inguinal hernia | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 1 | 2 |
| Anal fistula | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 1 | 1 |
| Colitis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 1 | 0 | 3 |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 0 | 1 | 3 |
| Proctalgia | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 3 | 0 | 2 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |
| Anal pruritus | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Mouth ulceration | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |
| Oesophagitis | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Abnormal faeces | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Anal ulcer | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |
| Anorectal discomfort | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Food poisoning | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Gastrointestinal pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Haematochezia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Oesophageal spasm | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Oral disorder | | | |

| | | | |
|------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Abdominal rigidity | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Anal skin tags | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anal spasm | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Anorectal disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chronic gastritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Diverticulum | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 3 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Erosive duodenitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Faeces pale | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastric ulcer | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gingival hypertrophy | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Gingival swelling | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haemorrhoids thrombosed | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperchlorhydria | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Irritable bowel syndrome | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Large intestine polyp | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lip haematoma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Lip swelling | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Loose tooth | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Mouth cyst | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oesophageal pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral pain | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Palatal disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Palatal ulcer | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Periodontal disease | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Rectal discharge | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rectal fissure | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Saliva altered | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Salivary hypersecretion | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Tongue disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tooth disorder | | | |

| | | | |
|--|------------------------|----------------------|------------------------|
| subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Tooth impacted subjects affected / exposed occurrences (all) | 1 / 411 (0.24%) 1 | 0 / 338 (0.00%) 0 | 0 / 411 (0.00%) 0 |
| Ulcerative gastritis subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Skin and subcutaneous tissue disorders | | | |
| Rash subjects affected / exposed occurrences (all) | 18 / 411 (4.38%) 22 | 1 / 338 (0.30%) 1 | 19 / 411 (4.62%) 23 |
| Pruritus subjects affected / exposed occurrences (all) | 17 / 411 (4.14%) 18 | 5 / 338 (1.48%) 5 | 10 / 411 (2.43%) 10 |
| Acne subjects affected / exposed occurrences (all) | 9 / 411 (2.19%) 9 | 2 / 338 (0.59%) 2 | 8 / 411 (1.95%) 9 |
| Eczema subjects affected / exposed occurrences (all) | 7 / 411 (1.70%) 9 | 1 / 338 (0.30%) 1 | 7 / 411 (1.70%) 10 |
| Night sweats subjects affected / exposed occurrences (all) | 5 / 411 (1.22%) 5 | 2 / 338 (0.59%) 2 | 8 / 411 (1.95%) 8 |
| Alopecia subjects affected / exposed occurrences (all) | 5 / 411 (1.22%) 5 | 4 / 338 (1.18%) 4 | 4 / 411 (0.97%) 4 |
| Seborrhoeic dermatitis subjects affected / exposed occurrences (all) | 3 / 411 (0.73%) 3 | 1 / 338 (0.30%) 1 | 8 / 411 (1.95%) 9 |
| Dry skin subjects affected / exposed occurrences (all) | 5 / 411 (1.22%) 5 | 1 / 338 (0.30%) 1 | 5 / 411 (1.22%) 5 |
| Dermatitis subjects affected / exposed occurrences (all) | 3 / 411 (0.73%) 3 | 2 / 338 (0.59%) 2 | 3 / 411 (0.73%) 3 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Dermatitis contact | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 4 | 1 | 3 |
| Skin lesion | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 4 / 411 (0.97%) |
| occurrences (all) | 2 | 1 | 5 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 3 | 0 | 3 |
| Urticaria | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 3 | 1 | 2 |
| Intertrigo | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 1 | 1 |
| Rosacea | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 1 | 0 | 3 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Erythema | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Psoriasis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |
| Rash papular | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 3 | 0 | 1 |
| Actinic keratosis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Dermatitis allergic | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Drug eruption | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Dyshidrotic eczema | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Eczema nummular | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Facial wasting | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Macule | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Neurodermatitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Pityriasis rosea | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Rash pruritic | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 2 |
| Skin fissures | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Acne conglobata | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|-------------------------------|-----------------|-----------------|-----------------|
| Acne cystic | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Alopecia areata | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Angioedema | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cutaneous lupus erythematosus | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dermal cyst | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Dermatosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eczema asteatotic | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Hidradenitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hyperkeratosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Lentigo | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Lipoatrophy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mechanical urticaria | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---------------------------------------|-----------------|-----------------|-----------------|
| Nail discolouration | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Nail ridging | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Papule | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Penile ulceration | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Pityriasis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Post inflammatory pigmentation change | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pruritus generalised | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash erythematous | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash generalised | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scab | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin burning sensation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin exfoliation | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin mass | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin plaque | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Spider naevus | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Telangiectasia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Toxic skin eruption | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Vitiligo | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 0 / 338 (0.00%) | 4 / 411 (0.97%) |
| occurrences (all) | 5 | 0 | 5 |
| Urethral discharge | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 3 / 411 (0.73%) |
| occurrences (all) | 1 | 2 | 3 |
| Haematuria | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 0 | 2 |
| Micturition urgency | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 1 | 1 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 2 | 1 |
| Leukocyturia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Urethral pain | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Polyuria | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |

| | | | |
|------------------------------|-----------------|-----------------|-----------------|
| Proteinuria | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Renal colic | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Glycosuria | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Microalbuminuria | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Renal impairment | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tubulointerstitial nephritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Urethral haemorrhage | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urethral stenosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary hesitation | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urine flow decreased | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|------------------|------------------|------------------|
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Goitre | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Androgen deficiency | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Basedow's disease | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypogonadism | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Thyroid mass | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 24 / 411 (5.84%) | 10 / 338 (2.96%) | 26 / 411 (6.33%) |
| occurrences (all) | 27 | 15 | 29 |
| Arthralgia | | | |
| subjects affected / exposed | 11 / 411 (2.68%) | 7 / 338 (2.07%) | 14 / 411 (3.41%) |
| occurrences (all) | 13 | 8 | 17 |
| Tendonitis | | | |
| subjects affected / exposed | 7 / 411 (1.70%) | 5 / 338 (1.48%) | 9 / 411 (2.19%) |
| occurrences (all) | 7 | 5 | 9 |
| Myalgia | | | |
| subjects affected / exposed | 10 / 411 (2.43%) | 3 / 338 (0.89%) | 7 / 411 (1.70%) |
| occurrences (all) | 10 | 3 | 7 |
| Pain in extremity | | | |

| | | | |
|--------------------------------|-----------------|-----------------|------------------|
| subjects affected / exposed | 7 / 411 (1.70%) | 1 / 338 (0.30%) | 10 / 411 (2.43%) |
| occurrences (all) | 7 | 1 | 11 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 2 / 338 (0.59%) | 7 / 411 (1.70%) |
| occurrences (all) | 5 | 2 | 7 |
| Osteopenia | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 5 / 338 (1.48%) | 7 / 411 (1.70%) |
| occurrences (all) | 2 | 5 | 7 |
| Neck pain | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 2 / 338 (0.59%) | 5 / 411 (1.22%) |
| occurrences (all) | 4 | 2 | 8 |
| Muscle spasms | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 4 / 411 (0.97%) |
| occurrences (all) | 3 | 2 | 4 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 6 | 1 | 3 |
| Bursitis | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 3 | 2 | 2 |
| Osteoarthritis | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 1 / 411 (0.24%) |
| occurrences (all) | 3 | 3 | 1 |
| Osteoporosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 3 / 338 (0.89%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 3 | 2 |
| Flank pain | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 2 | 1 | 5 |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 1 | 1 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Joint swelling | | | |

| | | | |
|------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Muscle contracture | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Plantar fasciitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 2 | 1 |
| Synovial cyst | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Intervertebral disc disorder | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Limb discomfort | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Spinal pain | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Bone erosion | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Bone pain | | | |

| | | | |
|----------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chondritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dupuytren's contracture | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Enthesopathy | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Fasciitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Fistula | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Foot deformity | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Gouty arthritis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Groin pain | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Intervertebral disc degeneration | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Jaw disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Joint stiffness | | | |

| | | | |
|------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle fatigue | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Muscle tightness | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle twitching | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Myosclerosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Myositis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Osteochondrosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 3 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Periarthritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Plantar fascial fibromatosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psoriatic arthropathy | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scoliosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Torticollis | | | |

| | | | |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 411 (0.00%) 0 | 0 / 338 (0.00%) 0 | 1 / 411 (0.24%) 1 |
| Infections and infestations | | | |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 54 / 411 (13.14%) | 24 / 338 (7.10%) | 54 / 411 (13.14%) |
| occurrences (all) | 73 | 27 | 77 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 34 / 411 (8.27%) | 27 / 338 (7.99%) | 31 / 411 (7.54%) |
| occurrences (all) | 43 | 36 | 38 |
| Syphilis | | | |
| subjects affected / exposed | 24 / 411 (5.84%) | 24 / 338 (7.10%) | 28 / 411 (6.81%) |
| occurrences (all) | 25 | 30 | 30 |
| Bronchitis | | | |
| subjects affected / exposed | 24 / 411 (5.84%) | 15 / 338 (4.44%) | 22 / 411 (5.35%) |
| occurrences (all) | 33 | 16 | 25 |
| Sinusitis | | | |
| subjects affected / exposed | 25 / 411 (6.08%) | 12 / 338 (3.55%) | 16 / 411 (3.89%) |
| occurrences (all) | 36 | 19 | 18 |
| Gastroenteritis | | | |
| subjects affected / exposed | 18 / 411 (4.38%) | 10 / 338 (2.96%) | 18 / 411 (4.38%) |
| occurrences (all) | 21 | 11 | 23 |
| Influenza | | | |
| subjects affected / exposed | 16 / 411 (3.89%) | 7 / 338 (2.07%) | 22 / 411 (5.35%) |
| occurrences (all) | 17 | 7 | 23 |
| Pharyngitis | | | |
| subjects affected / exposed | 23 / 411 (5.60%) | 9 / 338 (2.66%) | 14 / 411 (3.41%) |
| occurrences (all) | 31 | 9 | 16 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 19 / 411 (4.62%) | 5 / 338 (1.48%) | 12 / 411 (2.92%) |
| occurrences (all) | 19 | 9 | 14 |
| Rhinitis | | | |
| subjects affected / exposed | 13 / 411 (3.16%) | 7 / 338 (2.07%) | 13 / 411 (3.16%) |
| occurrences (all) | 20 | 8 | 15 |
| Oral herpes | | | |
| subjects affected / exposed | 8 / 411 (1.95%) | 7 / 338 (2.07%) | 13 / 411 (3.16%) |
| occurrences (all) | 9 | 8 | 17 |

| | | | |
|-----------------------------------|------------------|-----------------|------------------|
| Conjunctivitis | | | |
| subjects affected / exposed | 8 / 411 (1.95%) | 8 / 338 (2.37%) | 11 / 411 (2.68%) |
| occurrences (all) | 8 | 9 | 11 |
| Urinary tract infection | | | |
| subjects affected / exposed | 12 / 411 (2.92%) | 4 / 338 (1.18%) | 7 / 411 (1.70%) |
| occurrences (all) | 14 | 4 | 8 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 11 / 411 (2.68%) | 4 / 338 (1.18%) | 7 / 411 (1.70%) |
| occurrences (all) | 13 | 6 | 8 |
| Urethritis | | | |
| subjects affected / exposed | 9 / 411 (2.19%) | 5 / 338 (1.48%) | 8 / 411 (1.95%) |
| occurrences (all) | 10 | 6 | 10 |
| Chlamydial infection | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 7 / 338 (2.07%) | 9 / 411 (2.19%) |
| occurrences (all) | 6 | 8 | 13 |
| Gonorrhoea | | | |
| subjects affected / exposed | 7 / 411 (1.70%) | 8 / 338 (2.37%) | 6 / 411 (1.46%) |
| occurrences (all) | 8 | 9 | 7 |
| Herpes zoster | | | |
| subjects affected / exposed | 9 / 411 (2.19%) | 2 / 338 (0.59%) | 9 / 411 (2.19%) |
| occurrences (all) | 9 | 2 | 9 |
| Gingivitis | | | |
| subjects affected / exposed | 8 / 411 (1.95%) | 0 / 338 (0.00%) | 11 / 411 (2.68%) |
| occurrences (all) | 8 | 0 | 11 |
| Tonsillitis | | | |
| subjects affected / exposed | 10 / 411 (2.43%) | 5 / 338 (1.48%) | 4 / 411 (0.97%) |
| occurrences (all) | 10 | 8 | 4 |
| Folliculitis | | | |
| subjects affected / exposed | 6 / 411 (1.46%) | 4 / 338 (1.18%) | 8 / 411 (1.95%) |
| occurrences (all) | 7 | 4 | 9 |
| Ear infection | | | |
| subjects affected / exposed | 7 / 411 (1.70%) | 2 / 338 (0.59%) | 7 / 411 (1.70%) |
| occurrences (all) | 7 | 2 | 11 |
| Genital herpes | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 5 / 338 (1.48%) | 4 / 411 (0.97%) |
| occurrences (all) | 6 | 6 | 5 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Pneumonia | | | |
| subjects affected / exposed | 8 / 411 (1.95%) | 2 / 338 (0.59%) | 4 / 411 (0.97%) |
| occurrences (all) | 8 | 2 | 4 |
| Tooth infection | | | |
| subjects affected / exposed | 7 / 411 (1.70%) | 3 / 338 (0.89%) | 4 / 411 (0.97%) |
| occurrences (all) | 8 | 3 | 4 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 6 / 411 (1.46%) | 3 / 338 (0.89%) | 4 / 411 (0.97%) |
| occurrences (all) | 7 | 3 | 4 |
| Secondary syphilis | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 5 / 338 (1.48%) | 4 / 411 (0.97%) |
| occurrences (all) | 4 | 5 | 5 |
| Cellulitis | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 2 / 338 (0.59%) | 4 / 411 (0.97%) |
| occurrences (all) | 5 | 2 | 5 |
| Herpes simplex | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 3 / 338 (0.89%) | 7 / 411 (1.70%) |
| occurrences (all) | 1 | 5 | 8 |
| Herpes virus infection | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 3 / 338 (0.89%) | 5 / 411 (1.22%) |
| occurrences (all) | 3 | 5 | 8 |
| Onychomycosis | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 3 / 338 (0.89%) | 4 / 411 (0.97%) |
| occurrences (all) | 5 | 3 | 4 |
| Fungal skin infection | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 0 / 338 (0.00%) | 5 / 411 (1.22%) |
| occurrences (all) | 5 | 0 | 5 |
| Urethritis gonococcal | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 3 / 338 (0.89%) | 5 / 411 (1.22%) |
| occurrences (all) | 2 | 3 | 5 |
| Viral infection | | | |
| subjects affected / exposed | 6 / 411 (1.46%) | 0 / 338 (0.00%) | 4 / 411 (0.97%) |
| occurrences (all) | 6 | 0 | 4 |
| Furuncle | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 4 / 411 (0.97%) |
| occurrences (all) | 3 | 2 | 5 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Otitis externa | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 3 / 338 (0.89%) | 5 / 411 (1.22%) |
| occurrences (all) | 1 | 3 | 7 |
| Tooth abscess | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 2 / 338 (0.59%) | 3 / 411 (0.73%) |
| occurrences (all) | 4 | 3 | 3 |
| Tinea infection | | | |
| subjects affected / exposed | 5 / 411 (1.22%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 5 | 0 | 3 |
| Anal chlamydia infection | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 3 / 338 (0.89%) | 1 / 411 (0.24%) |
| occurrences (all) | 3 | 3 | 1 |
| Lymphogranuloma venereum | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 5 / 411 (1.22%) |
| occurrences (all) | 0 | 2 | 5 |
| Otitis media | | | |
| subjects affected / exposed | 4 / 411 (0.97%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 4 | 1 | 4 |
| Skin infection | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 3 / 338 (0.89%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 3 | 2 |
| Tinea versicolour | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 3 | 2 | 2 |
| Acarodermatitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 5 / 411 (1.22%) |
| occurrences (all) | 1 | 0 | 5 |
| Laryngitis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 3 / 411 (0.73%) |
| occurrences (all) | 2 | 1 | 3 |
| Anal abscess | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 1 | 3 |
| Erysipelas | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 1 | 2 |

| | | | |
|-----------------------------------|-----------------|-----------------|-----------------|
| Genital infection fungal | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 4 / 338 (1.18%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 5 | 0 |
| Infection | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 3 | 0 | 2 |
| Labyrinthitis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 1 | 2 |
| Proctitis gonococcal | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 2 | 2 |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 3 | 1 | 1 |
| Tinea cruris | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 2 | 2 |
| Fungal infection | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 3 / 411 (0.73%) |
| occurrences (all) | 1 | 0 | 3 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 4 | 0 |
| Orchitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 1 | 2 |
| Pharyngitis streptococcal | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 1 | 2 |
| Rash pustular | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 2 | 2 |
| Staphylococcal infection | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 2 | 0 | 2 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Tinea pedis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 1 | 1 |
| Abscess | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 4 | 0 | 1 |
| Acute hepatitis C | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Acute sinusitis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |
| Balanitis candida | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Cystitis | | | |
| subjects affected / exposed | 3 / 411 (0.73%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Epididymitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Giardiasis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Helicobacter infection | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 2 |
| Hordeolum | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 1 | 0 | 4 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Localised infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 1 | 2 |
| Lung infection | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Parotitis | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Pharyngotonsillitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Pilonidal cyst | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Primary syphilis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 2 | 1 |
| Tracheitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Angular cheilitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Beta haemolytic streptococcal infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Cervicitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Chronic sinusitis | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 2 |
| Dermatophytosis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Eye infection | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Gastroenteritis shigella | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Genital herpes simplex | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Genital infection bacterial | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 2 / 338 (0.59%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Helicobacter gastritis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hepatitis A | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hepatitis C | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Infected bite | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 3 |
| Infection parasitic | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Molluscum contagiosum | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Oral infection | | | |

| | | | |
|--------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Parasitic gastroenteritis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Proctitis chlamydial | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 0 | 1 |
| Vulvovaginal mycotic infection | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Abscess oral | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Amoebiasis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Asymptomatic bacteriuria | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Bacterial disease carrier | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Bacterial infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Bacterial vaginosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Bacteriuria | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Body tinea | | | |

| | | | |
|----------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 2 |
| Campylobacter gastroenteritis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Campylobacter infection | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Carbuncle | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Cervicitis human papilloma virus | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chronic hepatitis C | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Chronic tonsillitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Conjunctivitis viral | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dysentery | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Ear infection fungal | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Enterobiasis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Enterovirus infection | | | |

| | | | |
|-----------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastroenteritis clostridial | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal viral infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Genitourinary chlamydia infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Genitourinary tract infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Groin abscess | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hepatitis E | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hepatitis viral | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Impetigo | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Infected cyst | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Latent syphilis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Latent tuberculosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lung abscess | | | |

| | | | |
|------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ophthalmic herpes simplex | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oral viral infection | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oropharyngeal gonococcal infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Papilloma viral infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Pericoronitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Periorbital cellulitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Peritonsillar abscess | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Pharyngitis bacterial | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pneumonia cytomegaloviral | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Post procedural infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Proctitis bacterial | | | |

| | | | |
|-----------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pulpitis dental | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pyelonephritis chronic | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyuria | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Scrotal abscess | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 2 |
| Sexually transmitted disease | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sialoadenitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sinobronchitis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Sycosis barbae | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tonsillitis bacterial | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Tonsillitis streptococcal | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urethritis chlamydial | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary tract infection bacterial | | | |

| | | | |
|------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Vaginitis gardnerella | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Viral pharyngitis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vulvovaginal candidiasis | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Yersinia infection | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Metabolism and nutrition disorders | | | |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 7 / 411 (1.70%) | 7 / 338 (2.07%) | 6 / 411 (1.46%) |
| occurrences (all) | 7 | 7 | 6 |
| Decreased appetite | | | |
| subjects affected / exposed | 6 / 411 (1.46%) | 1 / 338 (0.30%) | 8 / 411 (1.95%) |
| occurrences (all) | 6 | 1 | 9 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 4 / 338 (1.18%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 3 / 338 (0.89%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 5 | 0 |
| Gout | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Hyperlipidaemia | | | |
| subjects affected / exposed | 2 / 411 (0.49%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 2 | 0 | 1 |

| | | | |
|--------------------------------------|-----------------|-----------------|-----------------|
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 1 | 1 | 1 |
| Dyslipidaemia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 1 | 1 |
| Increased appetite | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 2 / 411 (0.49%) |
| occurrences (all) | 0 | 0 | 2 |
| Alcohol intolerance | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Body fat disorder | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dehydration | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Food intolerance | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperlipasaemia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Hypovitaminosis | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Lactase deficiency | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 1 / 338 (0.30%) | 0 / 411 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Obesity | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Polydipsia | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 1 / 411 (0.24%) | 0 / 338 (0.00%) | 0 / 411 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vitamin B12 deficiency | | | |
| subjects affected / exposed | 0 / 411 (0.00%) | 0 / 338 (0.00%) | 1 / 411 (0.24%) |
| occurrences (all) | 0 | 0 | 1 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|---|
| 29 October 2010 | Amendment 01: Country Specific Amendment for the United Kingdom. |
| 14 January 2011 | Amendment 02: This amendment included reference to an Independent Data Monitoring Committee (IDMC) which regularly review targeted safety information. Additionally, standard hematology and clinical chemistry laboratory assessments were made required for all participants at the Week 2 study visit. Minor clarifications and corrections were incorporated. |
| 10 October 2011 | Amendment 03: This amendment allowed for a change in the management of participants with protocol-defined virologic failure. Additional follow-up assessments were added to the Liver Chemistry Stopping criteria panel. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported